These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 37124559)

  • 1. SGK1 inhibition attenuated the action potential duration in patient- and genotype-specific re-engineered heart cells with congenital long QT syndrome.
    Kim M; Das S; Tester DJ; Pradhananga S; Hamrick SK; Gao X; Srinivasan D; Sager PT; Ackerman MJ
    Heart Rhythm O2; 2023 Apr; 4(4):268-274. PubMed ID: 37124559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SGK1 inhibition attenuates the action potential duration in reengineered heart cell models of drug-induced QT prolongation.
    Kim M; Sager PT; Tester DJ; Pradhananga S; Hamrick SK; Srinivasan D; Das S; Ackerman MJ
    Heart Rhythm; 2023 Apr; 20(4):589-595. PubMed ID: 36610526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene- and variant-specific efficacy of serum/glucocorticoid-regulated kinase 1 inhibition in long QT syndrome types 1 and 2.
    Giannetti F; Barbieri M; Shiti A; Casini S; Sager PT; Das S; Pradhananga S; Srinivasan D; Nimani S; Alerni N; Louradour J; Mura M; Gnecchi M; Brink P; Zehender M; Koren G; Zaza A; Crotti L; Wilde AAM; Schwartz PJ; Remme CA; Gepstein L; Sala L; Odening KE
    Europace; 2023 May; 25(5):. PubMed ID: 37099628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genome sequencing in a genetically elusive multigenerational long QT syndrome pedigree identifies a novel LQT2-causative deeply intronic KCNH2 variant.
    Tobert KE; Tester DJ; Zhou W; Haglund-Turnquist CM; Giudicessi JR; Ackerman MJ
    Heart Rhythm; 2022 Jun; 19(6):998-1007. PubMed ID: 35144019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional characterization and identification of a therapeutic for a novel SCN5A-F1760C variant causing type 3 long QT syndrome refractory to all guideline-directed therapies.
    Stutzman MJ; Gao X; Kim M; Ye D; Zhou W; Tester DJ; Giudicessi JR; Shannon K; Ackerman MJ
    Heart Rhythm; 2023 May; 20(5):709-717. PubMed ID: 36731785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-specific, re-engineered cardiomyocyte model confirms the circumstance-dependent arrhythmia risk associated with the African-specific common SCN5A polymorphism p.S1103Y: Implications for the increased sudden deaths observed in black individuals during the COVID-19 pandemic.
    Hamrick SK; John Kim CS; Tester DJ; Giudicessi JR; Ackerman MJ
    Heart Rhythm; 2022 May; 19(5):822-827. PubMed ID: 34979239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Promise and Potential Peril With Lumacaftor for the Trafficking Defective Type 2 Long-QT Syndrome-Causative Variants, p.G604S, p.N633S, and p.R685P, Using Patient-Specific Re-Engineered Cardiomyocytes.
    O'Hare BJ; John Kim CS; Hamrick SK; Ye D; Tester DJ; Ackerman MJ
    Circ Genom Precis Med; 2020 Oct; 13(5):466-475. PubMed ID: 32940533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a Patient-Specific p.D85N-Potassium Voltage-Gated Channel Subfamily E Member 1-Induced Pluripotent Stem Cell-Derived Cardiomyocyte Model for Drug-Induced Long QT Syndrome.
    Kim M; Ye D; John Kim CS; Zhou W; Tester DJ; Giudicessi JR; Ackerman MJ
    Circ Genom Precis Med; 2021 Jun; 14(3):e003234. PubMed ID: 34003017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression and Replacement Gene Therapy for
    Bains S; Zhou W; Dotzler SM; Martinez K; Kim CJ; Tester DJ; Ye D; Ackerman MJ
    Circ Genom Precis Med; 2022 Dec; 15(6):e003719. PubMed ID: 36252106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression-Replacement
    Dotzler SM; Kim CSJ; Gendron WAC; Zhou W; Ye D; Bos JM; Tester DJ; Barry MA; Ackerman MJ
    Circulation; 2021 Apr; 143(14):1411-1425. PubMed ID: 33504163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogenic mechanism and gene correction for LQTS-causing double mutations in KCNQ1 using a pluripotent stem cell model.
    Wang Z; Wang L; Liu W; Hu D; Gao Y; Ge Q; Liu X; Li L; Wang Y; Wang S; Li C
    Stem Cell Res; 2019 Jul; 38():101483. PubMed ID: 31226583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induced Pluripotent Stem Cell-Derived Cardiomyocytes with
    Hayama E; Furutani Y; Kawaguchi N; Seki A; Nagashima Y; Okita K; Takeuchi D; Matsuoka R; Inai K; Hagiwara N; Nakanishi T
    Biology (Basel); 2021 Oct; 10(10):. PubMed ID: 34681161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Injectable contraceptive Depo-Provera induces erratic beating patterns in patient-specific induced pluripotent stem cell-derived cardiomyocytes with long QT syndrome type 2.
    Pinsky AM; Gao X; Bains S; Kim CJ; Louradour J; Odening KE; Tester DJ; Giudicessi JR; Ackerman MJ
    Heart Rhythm; 2023 Jun; 20(6):910-917. PubMed ID: 36889623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of sodium channel block with mexiletine to reverse action potential prolongation in in vitro models of the long term QT syndrome.
    Sicouri S; Antzelevitch D; Heilmann C; Antzelevitch C
    J Cardiovasc Electrophysiol; 1997 Nov; 8(11):1280-90. PubMed ID: 9395171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the CACNA1C-R518C Missense Mutation in the Pathobiology of Long-QT Syndrome Using Human Induced Pluripotent Stem Cell Cardiomyocytes Shows Action Potential Prolongation and L-Type Calcium Channel Perturbation.
    Estes SI; Ye D; Zhou W; Dotzler SM; Tester DJ; Bos JM; Kim CSJ; Ackerman MJ
    Circ Genom Precis Med; 2019 Aug; 12(8):e002534. PubMed ID: 31430211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Curcumin, a dietary natural supplement, prolongs the action potential duration of KCNE1-D85N-induced pluripotent stem cell-derived cardiomyocytes.
    Martinez K; Smith A; Ye D; Zhou W; Tester DJ; Ackerman MJ
    Heart Rhythm; 2023 Apr; 20(4):580-586. PubMed ID: 36586707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular biology of the long QT syndrome: impact on management.
    Priori SG; Napolitano C; Paganini V; Cantù F; Schwartz PJ
    Pacing Clin Electrophysiol; 1997 Aug; 20(8 Pt 2):2052-7. PubMed ID: 9272507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genome Editing of Induced Pluripotent Stem Cells to Decipher Cardiac Channelopathy Variant.
    Garg P; Oikonomopoulos A; Chen H; Li Y; Lam CK; Sallam K; Perez M; Lux RL; Sanguinetti MC; Wu JC
    J Am Coll Cardiol; 2018 Jul; 72(1):62-75. PubMed ID: 29957233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gating properties of SCN5A mutations and the response to mexiletine in long-QT syndrome type 3 patients.
    Ruan Y; Liu N; Bloise R; Napolitano C; Priori SG
    Circulation; 2007 Sep; 116(10):1137-44. PubMed ID: 17698727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-Specific and Gene-Corrected Induced Pluripotent Stem Cell-Derived Cardiomyocytes Elucidate Single-Cell Phenotype of Short QT Syndrome.
    Guo F; Sun Y; Wang X; Wang H; Wang J; Gong T; Chen X; Zhang P; Su L; Fu G; Su J; Yang S; Lai R; Jiang C; Liang P
    Circ Res; 2019 Jan; 124(1):66-78. PubMed ID: 30582453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.